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Abstract Optical coherence tomography (OCT) is a high-
resolution imaging technique that is increasingly used for
intracoronary imaging to characterize coronary atherosclerotic
plaques and vascular responses after coronary stent implanta-
tion. Introduction of optical frequency-domain imaging (OFDI;
second generation OCT) has simplified practical use of this
novel imaging modality resulting in a more widespread avail-
ability in interventional cardiology. Here we highlight recent
insights into the acute and chronic vascular response after
coronary stent implantation by OCT imaging. OCT provides
cross-sectional images with approximately 10-fold higher res-
olution as compared to intravascular-ultrasound (IVUS), allow-
ing for precise evaluation of tissue coverage and malapposition
of coronary stent struts. More than 30 studies using OCT to
compare vascular responses to different stents have now been
reported. Recent studies have examined the relation between
OCT-image characteristics and tissue composition around stent
struts. OCT is used for evaluation of novel stent concepts, such
as bioengineered stents and bioabsorbable stents, where it
provides more accurate information than IVUS. While intra-
coronary OCT imaging is further developed, including faster
3D-OCT-image-reconstruction, larger OCT studies/registries
with standardized analysis will provide more insights into
clinical implications of observations from OCT-imaging after
coronary stent implantation.
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Introduction
Optical coherence tomography (OCT) is a near-infrared
light-based imaging modality [1] that is now quite widely
available in interventional cardiology. OCT provides high-
resolution cross-sectional images of the inner vascular wall
and surface of blood vessels with an approximately 10-fold
higher image resolution as compared to intravascular ultra-
sound (IVUS) [1]. OCT imaging uses an interferometry
technique based on time-delay measurements of the light
reflected or backscattered from the tissues [1]. There are two
processing modes used for intracoronary OCT imaging, i.e.
the first generation time-domain OCT imaging systems and
the more recently available second generation frequency-
domain OCT imaging systems, also called optical frequency
domain imaging (OFDI) [2, 3]. OFDI has made the appli-
cation of OCT in the clinical setting substantially easier, in
particular the faster image acquisition as compared to the
first-generation time-domain OCT imaging systems [4, 5].
Time-domain OCT and more recently OFDI have been used
to analyze the vascular response to coronary stenting in a
substantial number of studies, and the present article will
summarize important insights from these investigations.
OCT and Evaluation of Coronary Stent Healing: Focus
on Stent Strut Coverage and Strut Malapposition
While first generation drug-eluting stents reduced the need
for repeated revascularization, coronary stent healing was
also delayed, requiring prolonged double anti-platelet ther-
apy in these patients [6, 7]. Impaired coronary stent healing,
in particular the lack of stent endothelialization, has been
suggested as one important mechanism causing very late
stent thrombosis in patients receiving a first-generation
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drug-eluting stent (Cypher and Taxus) as suggested by path-
ological studies [8•]. Several autopsy studies have described
a markedly impaired neointimal healing of stent struts in
patients who had a fatal late or very late coronary stent
thrombosis [9, 10]. Delayed healing was observed in
patients after sirolimus and paclitaxel-eluting first-generation
stent implantation as compared to BMS implantation as evi-
dent by persistent fibrin deposition and substantially impaired
stent endothelialization [9, 10].
Intravascular ultrasound examination could not detect a
thin neointimal coverage in the majority of sirolimus-eluting
stent struts in the chronic phase raising the question to what
extent these stents indeed remained uncovered [11]. OCT
imaging clearly provided a substantially more detailed eval-
uation of coronary stent strut coverage as compared to the
IVUS analysis [11] (Fig. 1.). In an early study of 34 patients
who underwent coronary time-domain OCT and IVUS eval-
uation 6-month after sirolimus-eluting stent implantation the
prevalence of covered stent struts as detected by OCT but
undetectable by IVUS was 64 % [11]. Therefore, there has
been a great interest in the use of OCT for the assessment of
the vascular response after coronary stent implantation.
Moreover, intravascular ultrasound (IVUS) studies have
previously suggested a high prevalence of incomplete stent
apposition (ISA) in patients with very late stent thrombosis
after DES implantation [12, 13]. A meta-analysis of IVUS
studies who had a baseline exam and a follow-up exam has
indicated that the risk of late acquired stent malapposition is
substantially increased after DES implantation as compared
to BMS implantation, and late stent malapposition was
associated with late and very late stent thrombosis [12, 13].
Due to the high resolution for the identification of coro-
nary stent struts, OCT is likely capable to determine the
apposition and degree of malapposition of stents struts in
more detail (Fig. 2.). In a study using both, IVUS and OCT,
OCT was superior in detection of malapposition of stent
struts, likely due to its ability to detect small gaps between
stent struts and the vessel wall that may be missed by IVUS
[14]. The stent strut is considered malapposed by OCTwhen
the abluminal strut surface is separated from the luminal
contour [15••].
Importantly, OCT provides valuable insights providing a
potential explanation for the relation between stent malap-
position and stent thrombosis. In patients who had under-
gone first-generation sirolimus-eluting stent implantation it
was observed that incomplete stent strut apposition (ISA)
was associated with a substantially higher rate of impaired
stent healing and with the presence of OCT-detected small
thrombi at follow-up, further suggesting that stent strut
malapposition and subsequently impaired stent healing rep-
resents a substrate for late or very late stent thrombosis [14].
Moreover, another study using OCT in 178 patients at 9 to
13 months follow-up after implantation of different drug-
eluting stents supported the notion that a delayed stent strut
coverage was substantially more frequently observed (ap-
proximately 9-fold) in struts with incomplete stent strut
apposition or in non-apposed side-branch stent struts [16].
Gutiérrez-Chico et al. have performed a study examining the
relation between acute stent strut malapposition as detected
and quantified by OCT and stent strut coverage in the
follow-up exams at 6 to 13 months (including analysis of
66 stents) [17]. It was observed that the larger the initial
stent strut malapposition the greater the likelihood of a
delayed healing in the follow-up [17]. Interestingly, stent
struts with small degrees of acute malapposition (< 270 μm)
were covered and apposed in the follow-up exam [17].
As described in detail below, several studies have now
compared stent strut coverage and strut malapposition for
several types of coronary stents (i.e. DES and BMS), differ-
ent DES at different time points after implantation, and for
different clinical indications (i.e. stable CAD vs ACS) by
using coronary OCT imaging. However, it needs also to be
taken into account, as described in more detail below, that
besides the characteristics and design of the stent, the stent
implantation technique and the underlying clinical scenario
requiring stent implantation (i.e. ACS with thrombotic
Fig. 1 The high resolution of
OCT (axial resolution 10–
15 μm) allows for detection of
thin layers of stent strut
coverage and sensitive




stent struts; b, OCT image
demonstrating stent struts cov-
ered with a thin neointima layer
that is below the IVUS axial
resolution (100 μm). Asterisk
indicates OCT catheter. ST,
stent strut
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material vs stable coronary disease) likely also determine
the degree and time-line of stent healing.
Comparison of Stent Strut Coverage and Malapposition
Between DES vs BMS, Different DES, or in Patients
with Stable CAD vs an Acute Coronary Syndrome
There have now been more than 30 observational or ran-
domized studies reported using OCT to examine stent heal-
ing after coronary stent implantation, largely focusing on
detection of the percentage of uncovered stent struts and
stent struts with malapposition (for summary of randomized
studies see Table 1), and some of these recent observations
are described below.
OCT Studies Comparing DES vs BMS
The largest randomized study to date using OCT to compare
the vascular response after implantation of a DES (TAXUS
Express, paclitaxel-eluting stent) and an otherwise identical
bare-metal stent (Express BMS) is the OCT substudy of the
prospective, randomized Harmonizing Outcomes with Re-
vascularization and Stents in Acute Myocardial Infarction
(HORIZONS-AMI) trial in patients with ST-segment eleva-
tion myocardial infarction (STEMI) that has included 118
consecutive randomized patients [18]. The TAXUS Express,
paclitaxel-eluting stents (PESs) reduced neointimal hyper-
plasia, but had also a higher rate of uncovered and malap-
posed stent struts as compared with the otherwise identical
BMS when examined 13 months after stent implantation
Fig. 2 Very late in-stent
thrombosis after DES implan-
tation. a, malapposed stent
struts, that are at least partially
uncovered (red arrows); b,
magnification of malapposed
stent struts at least partially un-
covered or covered by protrud-
ing white thrombi. Asterisk
indicates OCT catheter. ST,
stent strut
Table 1 Randomized trials using OCT for evaluation of stent strut coverage and malapposition
Study Stent type N Follow-up
(months)
Uncovered stent struts (%) Stent strut malapposition
(%)
DES vs BMS
Guagliumi et al. [18] PES vs BMS 118 13 5.7 vs 1.1 0.9 vs 0.1
Guagliumi et al. [19] SES vs PES vs ZES vs BMS 77 6 8.1 vs 4.1 vs 0.1 vs 0.9 2.3 vs 2.3 vs 0.0 vs 0.1
Guagliumi et al. [20] ZES vs BMS 44 6 0.0 vs 2.0 0.0 vs 0.15
DES vs DES
Miyoshi et al. [52] SES vs PES 27 6 12.7 vs 6.6 1.4 vs 0.5
Moore et al. [53] Polymer-c. SES vs Non-pol. SES 24 3 11.7 vs 2.8 2.2 vs 1.2
Guagliumi et al. [54] PES vs B-PES HD 60 6 5.3 vs 7.0 1.4 vs 0.8
Barlis et al. [22] BES vs SES 56 9 1.8 vs 6.3
Gutierrez-Chico [23] BES vs SES 21 24 1.5 vs 1.8 0.1 vs 0.4
Gutierrez-Chico [24] R-ZES vs EES 58 13 7.4 vs 5.8 1.8 vs 1.4
Takano et al. [25] EES vs PES 42 6 2.3 vs 5.2 2.1 vs 5.7
DEB
Gutierrez-Chico [55] DCB+BMS vs BMS+DCB 26 6 8.1 vs 5.3
BES biolimus-eluting stent, BMS bare-metal stent, B-PES biolimus-eluting stent with biodegradable polymer, DCB drug-coated balloon, EES
everolimus-eluting stent, PES paclitaxel-eluting stent, PF-SES polymer-free sirolimus-eluting stent, R-ZES zotarolimus-eluting stent with slow-
release and Biolynx polymer (Resolute), SES sirolimus-eluting stent, ZES zotarolimus-eluting stent (Endeavor)
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[18]. This phenomenon is observed for most drug-eluting
stents, that suppress excessive neointima formation (i.e.
restenosis), but also have a delayed stent strut healing. The
fast-release zotarolimus-eluting stent (Endeavor) tested in
the studies by Guagliumi et al. as shown in the DES vs
BMS section of Table 1 [19, 20] had also a higher restenosis
rate. In fact, the same authors have compared this stent with
the later generation of zotarolimus-eluting, slow-release
stents (Resolute), that more efficiently suppressed restenosis,
and have observed a stronger suppression of the neointimal
response but also a higher proportion of uncovered and malap-
posed stent struts at the 6-monthOCT follow-upwith the newer
generation of the zotarolimus-eluting stents (Resolute) [21].
OCT Studies Comparing Different DES
Within the LEADERS trial an OCT substudy was performed
in 56 patients to compare stent strut coverage following im-
plantation of a biodegradable versus a durable polymer-coated
drug-eluting stent [22]. Stent strut coverage at a mean follow-
up of 9 months appeared to be more complete in patients after
implantation of biodegradable polymer-coated, biolimus-
eluting stents (BESs) when compared with the durable
polymer-coated sirolimus-eluting stents (SESs) [22]. A long-
term follow-up OCT exam suggested that after 24 months the
stent strut coverage was similar between the two stent types,
i.e. 1.5 % versus 1.8 % uncovered stent struts [23].
An OCT substudy of the RESOLUTE All Comers trial
has compared stent healing of the hydrophilic polymer-
coated zotarolimus-eluting stent (Resolute) with
fluoropolymer-coated everolimus-eluting stent (Xience V)
at 13-month follow-up [24]. There were no significant dif-
ferences observed with respect to stent strut tissue coverage
and malapposition at 13-month follow-up, e.g. 7.4 % and
5.8 % uncovered stent struts [24]. A recent prospective,
randomized OCT study has compared coronary stent healing
after everolimus-eluting stent (EES) and paclitaxel-eluting
stent (PES) implantation and has suggested a favorable stent
healing response after EES implantation in a 6 months
follow-up examination (Table 1) [25]. Several studies using
OCT to compare stent healing of different DES are summa-
rized in Table 1, suggesting that besides the stent implanta-
tion technique and the clinical scenario the design of DES
likely is important for the vascular healing response.
OCT Examination After DES-Implantation in Stable CAD
and Acute MI
Retrospective pathological and clinical coronary OCT im-
aging studies have observed a higher rate of uncovered and
malapposed stent struts in DES that were implanted during
an acute STEMI as compared to DES implanted in patients
with stable coronary disease [26–28], suggesting that the
clinical situation where stent implantation is performed
needs to be considered for the interpretation of the stent
healing response. Figure 3 shows an OCT in a patient with
NSTEMI before and after coronary stent implantation,
where thrombotic material is to be seen under stent struts
revealing one potential mechanism promoting malapposi-
tion in patients with an acute coronary syndrome (Fig. 3).
OCT Evaluation of New Stent Technologies, eg
Bioengineered Stents
OCT is being used to examine whether novel stent technol-
ogies may have an accelerated or favorable vascular healing
response. The above described data suggest that drug-
eluting stents that efficiently suppress restenosis have most-
ly some degree of delayed stent healing. Therefore there has
been substantial interest in designing bioengineered stents
with a potential to accelerate stent healing. The REMEDEE
OCT study is currently randomizing 60 patients with an
acute coronary syndrome to receive either a CD34+anti-
body covered, sirolimus-eluting stent (Genous Combo) or
an everolimus-eluting stent (Xience V or Promus) and eval-
uates the early stent healing response by OCT/OFDI at
2 month follow-up (ClinicalTrials.gov Identifier:
NCT01405287).
OCT Imaging After Stent Implantation: Tissue
Characterization Around Stent Struts
While the resolution of OCT is substantially greater as
compared to ultrasound and can be in the range of 10 μm
axial and 20–40 μm lateral resolution, it does not allow
detection of a single cell layer (such as the endothelium),
that might become possible with the microOCT systems that
have been examined in the experimental setting [29]. How-
ever, several studies have suggested a close relation between
the detection of stent strut coverage by OCT as compared to
histology [30•, 31, 32]. Moreover, there has been substantial
interest in OCT image characteristics that may aid in the
distinction between different tissues covering stent struts,
i.e. fibrin coverage with thrombotic material vs neointimal
coverage. Backscattering intensity and signal attenuation
may provide information for the further discrimination of
stent strut coverage tissue type, in particular a lower OCT
signal intensity has been observed for fibrin-covered stent
struts as compared to neointimal covered stent struts [30•,
31]. In a study of porcine coronary stent implantation we
have observed that fibrin-rich tissue as detected early after
porcine coronary stent implantation and confirmed by electron
microscopy had a substantially lower OCT signal-intensity
when compared to neointima-covered stent struts later after
implantation, that were covered by smooth muscle cell-rich
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tissue with extracellular matrix containing collagens [30•].
Nakano et al. have recently reported in a study using stents
obtained at autopsy that a lower signal intensity and a greater
signal attenuation was observed for fibrin as compared to
neointima-covered stent struts when examined by OFDI
[31]. Furthermore, the luminal surface appears more irregular
when stent struts are covered by fibrin accumulation as com-
pared to neointima [30•, 31]. It is likely that the further
characterization of the type of tissue coverage of the stent
struts will be important, since only neointima, but not fibrin-
coverage of stent struts can be considered as an effective stent
healing. For example, a recent study in patients with STEMI
has reported an OCT follow-up after 3–7 days and reported a
high percentage of stent struts that were covered with a thin
rim, making it likely that this may rather represent fibrin than
neointimal stent strut coverage [33].
OCT: AValuable Tool for Evaluation of Vascular
Response of Bioabsorbable Stents
The reproducibility of gray-scale IVUS was reported to be
lower as compared with OCT for detection of qualitative
findings after bioresorbable vascular scaffold (BVS) im-
plantation [34]. OCT is capable of an accurate assessment
of the polymeric struts, the changes in luminal and scaffold
dimensions, and the quantification of neointimal hyperplasia
[35••]. The amount of backscattering in OCT imaging
depends on the material and the progress of strut biodegra-
dation. Recently published studies have provided data with
respect to safety and feasibility of bioresorbable stents as
revealed by OCT [35••, 36]. Two years after bioabsorbable
everolimus-eluting coronary stent implantation in the AB-
SORB study OCT imaging suggested that the stents had
Fig. 3 This image illustrates
potential aspects of why an
acute coronary syndrome may
predispose to an impaired stent
healing: a, Red thrombus in the
culprit lesion of the proximal
segment of RCX in a patient
with NSTEMI; b, After stent
implantation stent struts with
underlying and protruding
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Fig. 4 In stent dissection and edge dissection after coronary stent implantation that can be detected by OCT and frequently would not be seen by
angiography or IVUS (red arrows). Asterisk indicates OCT catheter
been incorporated into the vessel wall and was largely bio-
absorbed; 34 % of the stent struts were no longer discernible
at all by OCT after 2 years, suggesting that they had been
completely bioabsorbed [35••]. The OCT/OFDI quantifica-
tion of the healing process after bioabsorbable stent implan-
tation has important differences as compared to the metal-
scaffold stents. Strut core areas do not produce dorsal shad-
ows which allows for a complete imaging of strut thickness
[37, 38].
OCT Examination of Stent Healing and Risk of Stent
Thrombosis
Late and very late stent thrombosis is a rare, but feared
complication after coronary stent implantation. Several
causes can lead to late or very late stent thrombosis, includ-
ing impaired stent healing (uncovered/malapposed stent
struts), but also neoatherosclerosis and rupture within the
stent [8•, 39]. As described above, autopsy studies have
suggested that the percentage of uncovered stent struts is
particularly high in patients who died from a stent throm-
bosis [8•, 39]. The clinical implications, however, of a
certain percentage of uncovered or malapposed stent struts
need to be further examined and evaluated. In this respect, a
recent case-controlled study has suggested a substantially
increased frequency and length of uncovered and malapposed
stent struts as assessed by OCT in patients with late stent
thrombosis after DES implantation (percentage of uncovered
stent struts 12.2 % vs. 4.1 %) [40•]. In pathological studies the
presence of >30 % uncovered stent-struts was highly predic-
tive of in-stent thrombosis after DES implantation [8•]. Ozaki
et al. reported, that incomplete stent apposition without neo-
intimal hyperplasia was significantly associated with the pres-
ence of OCT-detected thrombus at follow-up, and may
constitute a potent substrate for LIST [14].
Besides impaired stent healing, neoatherosclerosis may
also contribute to clinical events late after DES implantation
due to neointimal rupture as suggested by a recent study
using OCT [41].
OCTand Detection of Subclinical Dissections After Stent
Implantation (Edge Dissections)
Because of the high resolution of OCT small intimal dis-
sections, also termed small intimal disruptions, are more
frequently observed after coronary stent implantation by
OCT as compared to what is detected by angiography or
IVUS [42] (see example Fig. 4). Such subclinical dissec-
tions are detected within the stent, but often also at the stent
edges (i.e. edge dissections) [43]. There is no evidence that
such subclinical dissections as revealed by OCT should be
“sealed” by additional overlapping stents [43]. On the con-
trary, multiple overlapping stents are known to be associated
with stent strut malapposition and have been reported as a
predictor of LIST after DES [44]. In a study analyzing the
acute effects of coronary stenting by OCT in 80 vessels (and
73 patients), a stent edge dissection was detected in 20
vessels without clinical events during hospitalization [43].
A small study has reported the frequency of stent edge
dissection as detected by OCT or IVUS during acute stent
implantation and follow-up after approximately 6 months in
36 patients [45]. Notably, all OCT-detected stent edge dis-
sections were healed without thrombus formation at the late
follow-up [45], suggesting that small edge dissections
should not prompt additional stent implantation.
A recent study using OCT, however, has suggested that
intra-stent dissections (besides thin-cap fibroatheroma and
intra-stent thrombus) were associated with a higher risk of
periprocedural (type IVa) myocardial infarction in 50
patients with stable CAD or an NSTEMI [46].
Future Perspectives/Conclusions
OCT is a feasible and safe imaging modality for the detailed
evaluation of the acute and chronic vascular response after
coronary stent implantation, allowing detection of stent strut
coverage, strut malapposition, angiographically inapparent
thrombus formation, and small intimal ruptures [32, 47–50].
OCT reveals much more detail after coronary stent implan-
tation as compared to IVUS [51]. A remaining challenge is
to better define the clinical implications of the observations
made by OCT, that will likely require larger OCT studies
and registries with long-term follow-up.
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